<table>
<thead>
<tr>
<th>Security</th>
<th>Shares/Par</th>
<th>Value ($)</th>
<th>% of Net Assets</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>3,200,673</td>
<td>243,859,276</td>
<td>2.105%</td>
</tr>
<tr>
<td>Abcam</td>
<td>810,766</td>
<td>11,436,754</td>
<td>0.099%</td>
</tr>
<tr>
<td>Acadia Healthcare</td>
<td>614,778</td>
<td>11,281,176</td>
<td>0.097%</td>
</tr>
<tr>
<td>ACADIA Pharmaceuticals</td>
<td></td>
<td>2,047,189</td>
<td>1.075%</td>
</tr>
<tr>
<td>Acceleron Pharma</td>
<td></td>
<td>1,226,646</td>
<td>0.952%</td>
</tr>
<tr>
<td>Agilent Technologies</td>
<td></td>
<td>2,394,517</td>
<td>1.481%</td>
</tr>
<tr>
<td>Agios Pharmaceuticals</td>
<td></td>
<td>502,733</td>
<td>0.154%</td>
</tr>
<tr>
<td>Amimmune Therapeutics</td>
<td></td>
<td>991,910</td>
<td>0.097%</td>
</tr>
<tr>
<td>Allergan</td>
<td></td>
<td>1,612,150</td>
<td>0.713%</td>
</tr>
<tr>
<td>Alkermes</td>
<td></td>
<td>2,387,118</td>
<td>1.242%</td>
</tr>
<tr>
<td>Allakos</td>
<td></td>
<td>4,272,364</td>
<td>0.037%</td>
</tr>
<tr>
<td>Allogene therapeutics</td>
<td></td>
<td>724,911</td>
<td>0.122%</td>
</tr>
<tr>
<td>Alnylam Pharmaceuticals</td>
<td></td>
<td>1,238,635</td>
<td>1.164%</td>
</tr>
<tr>
<td>Amedisys</td>
<td></td>
<td>212,138</td>
<td>0.336%</td>
</tr>
<tr>
<td>Amgen</td>
<td></td>
<td>1,416,159</td>
<td>2.479%</td>
</tr>
<tr>
<td>Anheuser-Busch</td>
<td></td>
<td>633,460</td>
<td>1.426%</td>
</tr>
<tr>
<td>Agens, ADR</td>
<td></td>
<td>478,590</td>
<td>0.111%</td>
</tr>
<tr>
<td>Aclara, ADR</td>
<td></td>
<td>675,208</td>
<td>0.768%</td>
</tr>
<tr>
<td>Ascendis Pharma, ADR</td>
<td>1,048,837</td>
<td>118,109,535</td>
<td>1.020%</td>
</tr>
<tr>
<td>Astellas Pharma</td>
<td></td>
<td>2,191,100</td>
<td>0.291%</td>
</tr>
<tr>
<td>AstraZeneca, ADR</td>
<td></td>
<td>3,959,860</td>
<td>1.527%</td>
</tr>
<tr>
<td>Azelio</td>
<td></td>
<td>728,975</td>
<td>0.096%</td>
</tr>
<tr>
<td>Avantor</td>
<td></td>
<td>2,642,300</td>
<td>0.091%</td>
</tr>
<tr>
<td>Avrtp</td>
<td></td>
<td>537,216</td>
<td>0.015%</td>
</tr>
<tr>
<td>Avrto</td>
<td></td>
<td>4,097,056</td>
<td>0.442%</td>
</tr>
<tr>
<td>Avrobio</td>
<td></td>
<td>251,967</td>
<td>0.034%</td>
</tr>
<tr>
<td>Bayer</td>
<td></td>
<td>269,078</td>
<td>0.037%</td>
</tr>
<tr>
<td>Baxter Dickinson And</td>
<td></td>
<td>385,926</td>
<td>0.183%</td>
</tr>
<tr>
<td>Baxter, Dickinson &amp; Company</td>
<td></td>
<td>1,709,120</td>
<td>3.951%</td>
</tr>
<tr>
<td>Biogen</td>
<td></td>
<td>726,975</td>
<td>1.991%</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td></td>
<td>313,881</td>
<td>0.833%</td>
</tr>
<tr>
<td>Blueprint Medicines</td>
<td></td>
<td>423,251</td>
<td>0.168%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td></td>
<td>2,679,302</td>
<td>1.085%</td>
</tr>
<tr>
<td>Bruker</td>
<td></td>
<td>728,975</td>
<td>0.294%</td>
</tr>
<tr>
<td>Cara Therapeutics</td>
<td></td>
<td>844,398</td>
<td>0.098%</td>
</tr>
<tr>
<td>Cellective</td>
<td></td>
<td>730,259</td>
<td>0.328%</td>
</tr>
<tr>
<td>Cemene</td>
<td></td>
<td>4,610,330</td>
<td>2.314%</td>
</tr>
<tr>
<td>Chugai Pharmaceutical</td>
<td></td>
<td>766,200</td>
<td>0.765%</td>
</tr>
<tr>
<td>Cigna</td>
<td></td>
<td>1,525,822</td>
<td>0.205%</td>
</tr>
<tr>
<td>Cooper Companies</td>
<td></td>
<td>481,401</td>
<td>0.622%</td>
</tr>
<tr>
<td>Color Therapeutics</td>
<td></td>
<td>212,612</td>
<td>0.078%</td>
</tr>
<tr>
<td>Daichy Seikyo</td>
<td></td>
<td>1,125,200</td>
<td>0.667%</td>
</tr>
<tr>
<td>Danaher</td>
<td></td>
<td>1,796,021</td>
<td>2.146%</td>
</tr>
<tr>
<td>Dendral therapeutics</td>
<td></td>
<td>487,816</td>
<td>0.074%</td>
</tr>
<tr>
<td>Dendal Tech</td>
<td></td>
<td>285,592</td>
<td>0.028%</td>
</tr>
<tr>
<td>Dexcom</td>
<td></td>
<td>466,784</td>
<td>1.065%</td>
</tr>
<tr>
<td>DSSom</td>
<td></td>
<td>266,346</td>
<td>0.303%</td>
</tr>
<tr>
<td>DSSoma Pharmaceuticals</td>
<td></td>
<td>328,121</td>
<td>0.163%</td>
</tr>
<tr>
<td>Elaia</td>
<td></td>
<td>652,500</td>
<td>0.412%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td></td>
<td>66,691</td>
<td>0.024%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td></td>
<td>1,035,567</td>
<td>0.325%</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td></td>
<td>1,580,234</td>
<td>0.372%</td>
</tr>
<tr>
<td>Enanta Pharmaceuticals</td>
<td></td>
<td>425,409</td>
<td>0.189%</td>
</tr>
<tr>
<td>Ensil Holdings</td>
<td></td>
<td>2,522,939</td>
<td>0.325%</td>
</tr>
<tr>
<td>Exact Sciences</td>
<td></td>
<td>1,300,037</td>
<td>0.651%</td>
</tr>
<tr>
<td>Eversi</td>
<td></td>
<td>3,765,688</td>
<td>0.560%</td>
</tr>
<tr>
<td>Fate Therapeutics</td>
<td></td>
<td>473,948</td>
<td>0.091%</td>
</tr>
<tr>
<td>FibroGen</td>
<td></td>
<td>593,633</td>
<td>0.178%</td>
</tr>
<tr>
<td>G1 therapeutics</td>
<td></td>
<td>236,209</td>
<td>0.022%</td>
</tr>
<tr>
<td>Galapagos</td>
<td></td>
<td>203,484</td>
<td>0.045%</td>
</tr>
<tr>
<td>GenMark Diagnostics</td>
<td></td>
<td>1,275,317</td>
<td>0.049%</td>
</tr>
<tr>
<td>Global Blood Therapeutics</td>
<td></td>
<td>1,001,999</td>
<td>0.442%</td>
</tr>
<tr>
<td>Guardian Health</td>
<td></td>
<td>590,720</td>
<td>0.220%</td>
</tr>
<tr>
<td>Stock Name</td>
<td>Shares</td>
<td>Market Cap</td>
<td>% of Total</td>
</tr>
<tr>
<td>----------------------------</td>
<td>--------</td>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>GW Pharmaceuticals, ADR</td>
<td>194,194</td>
<td>17,055,569</td>
<td>0.147%</td>
</tr>
<tr>
<td>HCA Healthcare</td>
<td>1,662,938</td>
<td>149,414,979</td>
<td>1.290%</td>
</tr>
<tr>
<td>Homology Medicines</td>
<td>594,280</td>
<td>9,235,111</td>
<td>0.060%</td>
</tr>
<tr>
<td>HTG Molecular Diagnostics</td>
<td>399,073</td>
<td>321,449</td>
<td>0.003%</td>
</tr>
<tr>
<td>Humana</td>
<td>771,224</td>
<td>242,179,760</td>
<td>2.091%</td>
</tr>
<tr>
<td>IICU Medical</td>
<td>187,590</td>
<td>37,450,034</td>
<td>0.327%</td>
</tr>
<tr>
<td>Immunomedics</td>
<td>999,617</td>
<td>13,474,837</td>
<td>0.116%</td>
</tr>
<tr>
<td>Insys</td>
<td>2,161,927</td>
<td>158,317,914</td>
<td>1.367%</td>
</tr>
<tr>
<td>Intuitive Surgical</td>
<td>667,384</td>
<td>429,537,231</td>
<td>3.709%</td>
</tr>
<tr>
<td>Ionis Pharmaceuticals</td>
<td>768,533</td>
<td>36,336,240</td>
<td>0.314%</td>
</tr>
<tr>
<td>Karuna therapeutics</td>
<td>423,194</td>
<td>30,469,968</td>
<td>0.263%</td>
</tr>
<tr>
<td>Kodiak Sciences</td>
<td>1,109,573</td>
<td>52,926,632</td>
<td>0.457%</td>
</tr>
<tr>
<td>Krystal Biotech</td>
<td>265,037</td>
<td>11,460,200</td>
<td>0.099%</td>
</tr>
<tr>
<td>Lantheus Holdings</td>
<td>825,945</td>
<td>10,539,058</td>
<td>0.091%</td>
</tr>
<tr>
<td>Lonza Group</td>
<td>88,495</td>
<td>36,400,098</td>
<td>0.314%</td>
</tr>
<tr>
<td>Merck</td>
<td>2,618,277</td>
<td>193,756,232</td>
<td>1.673%</td>
</tr>
<tr>
<td>Mettler-Toledo International</td>
<td>50,273</td>
<td>34,714,009</td>
<td>0.300%</td>
</tr>
<tr>
<td>Micrometrix</td>
<td>507,176</td>
<td>11,297,349</td>
<td>0.098%</td>
</tr>
<tr>
<td>Micr Therapeutics</td>
<td>678,205</td>
<td>8,861,937</td>
<td>0.077%</td>
</tr>
<tr>
<td>Moderna Therapeutics</td>
<td>268,200</td>
<td>8,032,590</td>
<td>0.069%</td>
</tr>
<tr>
<td>M-Ont Medical</td>
<td>593,475</td>
<td>82,914,392</td>
<td>0.716%</td>
</tr>
<tr>
<td>Momenta Pharmaceuticals</td>
<td>786,650</td>
<td>21,396,880</td>
<td>0.185%</td>
</tr>
<tr>
<td>MolTora Biopharma</td>
<td>663,435</td>
<td>31,101,833</td>
<td>0.269%</td>
</tr>
<tr>
<td>Nektar Therapeutics</td>
<td>731,858</td>
<td>13,063,665</td>
<td>0.113%</td>
</tr>
<tr>
<td>Neurocrine Biosciences</td>
<td>1,136,177</td>
<td>98,336,119</td>
<td>0.849%</td>
</tr>
<tr>
<td>Neurocrine</td>
<td>647,750</td>
<td>64,762,045</td>
<td>0.559%</td>
</tr>
<tr>
<td>Novartis</td>
<td>932,386</td>
<td>76,920,785</td>
<td>0.664%</td>
</tr>
<tr>
<td>Novavax</td>
<td>651,981</td>
<td>29,081,426</td>
<td>0.251%</td>
</tr>
<tr>
<td>Ocata Therapeutics</td>
<td>409,176</td>
<td>11,297,349</td>
<td>0.098%</td>
</tr>
<tr>
<td>Orchard Therapeutics, ADR</td>
<td>678,205</td>
<td>8,861,937</td>
<td>0.077%</td>
</tr>
<tr>
<td>Pennex</td>
<td>625,843</td>
<td>8,861,937</td>
<td>0.077%</td>
</tr>
<tr>
<td>Pennumbra</td>
<td>350,000</td>
<td>56,615,860</td>
<td>0.489%</td>
</tr>
<tr>
<td>Pernix</td>
<td>11,699</td>
<td>562,605</td>
<td>0.005%</td>
</tr>
<tr>
<td>PTC Health Sciences</td>
<td>454,323</td>
<td>1,503,809</td>
<td>0.13%</td>
</tr>
<tr>
<td>Principia Biopharma</td>
<td>363,355</td>
<td>30,172,999</td>
<td>0.261%</td>
</tr>
<tr>
<td>Raretiming</td>
<td>358,792</td>
<td>21,396,880</td>
<td>0.185%</td>
</tr>
<tr>
<td>Rare Therapeutics</td>
<td>315,711</td>
<td>19,313,856</td>
<td>0.167%</td>
</tr>
<tr>
<td>Rubisc Synchronics</td>
<td>738,575</td>
<td>6,216,693</td>
<td>0.054%</td>
</tr>
<tr>
<td>Quadrax</td>
<td>737,986</td>
<td>13,063,665</td>
<td>0.113%</td>
</tr>
<tr>
<td>Quidel</td>
<td>680,955</td>
<td>66,516,180</td>
<td>0.574%</td>
</tr>
<tr>
<td>RAPT therapeutics</td>
<td>229,759</td>
<td>4,886,974</td>
<td>0.042%</td>
</tr>
<tr>
<td>RAPT therapeutics</td>
<td>178,102</td>
<td>3,598,818</td>
<td>0.031%</td>
</tr>
<tr>
<td>Rely Therapeutics</td>
<td>204,879</td>
<td>29,572,235</td>
<td>0.255%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td>475,975</td>
<td>232,413,833</td>
<td>2.007%</td>
</tr>
<tr>
<td>REGENXBIO</td>
<td>266,638</td>
<td>8,640,214</td>
<td>0.075%</td>
</tr>
<tr>
<td>Roche Holding</td>
<td>475,441</td>
<td>152,369,427</td>
<td>1.231%</td>
</tr>
<tr>
<td>Rocket Pharmaceuticals</td>
<td>563,589</td>
<td>8,141,067</td>
<td>0.070%</td>
</tr>
<tr>
<td>SAGE Therapeutics</td>
<td>672,488</td>
<td>19,313,856</td>
<td>0.167%</td>
</tr>
<tr>
<td>Sanatia Therapeutics</td>
<td>570,954</td>
<td>56,615,860</td>
<td>0.489%</td>
</tr>
<tr>
<td>Sartorius</td>
<td>216,810</td>
<td>51,834,094</td>
<td>0.448%</td>
</tr>
<tr>
<td>Scholar Rock Holding</td>
<td>147,636</td>
<td>1,787,872</td>
<td>0.015%</td>
</tr>
<tr>
<td>Seattle Genetics</td>
<td>1,371,782</td>
<td>158,276,207</td>
<td>1.367%</td>
</tr>
<tr>
<td>Shoulder Medical</td>
<td>1,025,085</td>
<td>34,012,320</td>
<td>0.294%</td>
</tr>
<tr>
<td>Skyler</td>
<td>1,037,655</td>
<td>256,004,181</td>
<td>2.110%</td>
</tr>
<tr>
<td>Tandem Diabetes Care</td>
<td>165,855</td>
<td>10,726,799</td>
<td>0.092%</td>
</tr>
<tr>
<td>Talefex</td>
<td>235,762</td>
<td>85,738,279</td>
<td>0.740%</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>1,480,921</td>
<td>419,389,136</td>
<td>3.606%</td>
</tr>
<tr>
<td>Tricel</td>
<td>845,885</td>
<td>18,609,470</td>
<td>0.161%</td>
</tr>
<tr>
<td>TRIP Government Reserve</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uptake Pharmaceuticals</td>
<td>794,833</td>
<td>35,305,114</td>
<td>0.305%</td>
</tr>
<tr>
<td>UnitedHealth Group</td>
<td>2,647,658</td>
<td>680,272,453</td>
<td>5.701%</td>
</tr>
<tr>
<td>Via Nova Systems</td>
<td>319,945</td>
<td>50,029,643</td>
<td>0.432%</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals</td>
<td>2,259,139</td>
<td>537,562,125</td>
<td>4.641%</td>
</tr>
<tr>
<td>Viva Life Sciences</td>
<td>60,784</td>
<td>5,816,746</td>
<td>0.056%</td>
</tr>
<tr>
<td>West Pharmaceutical Services</td>
<td>516,993</td>
<td>78,712,184</td>
<td>0.660%</td>
</tr>
<tr>
<td>Xencor</td>
<td>874,374</td>
<td>26,245,008</td>
<td>0.227%</td>
</tr>
<tr>
<td>Zai Lab, ADR</td>
<td>136,322</td>
<td>7,017,857</td>
<td>0.061%</td>
</tr>
</tbody>
</table>
Zimmer Biomet Holdings 282,857 28,591,186 0.247%
Zogenix 397,697 9,835,047 0.085%
Miscellaneous Securities ‡ 811,977,253
Total Investments in Securities 11,578,564,576

‡ At the discretion of the advisor, the identity of certain securities has been concealed to protect the fund's interests.

NET ASSETS 11,582,085,330

NET ASSET VALUE PER SHARE

Health Sciences Fund Shares 70.50
($10,569,722,454 / 149,922,277 Shares Outstanding)

Health Sciences Fund - I Class Shares 70.52
($1,012,362,876 / 14,356,401 Shares Outstanding)

ADR  American Depository Receipts
ADRs  American Depository Shares
AR  Auction Rate security with an interest rate reset feature through a modified Dutch auction at predetermined short-term intervals; rate shown is effective rate at period end
ARM  Adjustable Rate Mortgage
BAN  Bond Anticipation Note
CDA  Community Development Administration
CLN  Credit Linked Note
CMO  Collateralized Mortgage Obligation
COP  Certificate of Participation
DOT  Department of Transportation
EFA  Educational Facility Authority
ETC  Equipment Trust Certificate
FDR  Fiduciary Depository Receipt
FRN  Floating Rate Note
GDR  Global Depository Receipts
GDS  Global Depository Shares
GO  General Obligation
HDA  Housing Development Authority
HEFA  Health & Education Facility Authority
HFA  Health Facility Authority
HFC  Housing Finance Corp
HPFA  Health Facility Financing Authority
HHEFA  Health & Higher Education Facility Authority
IDA  Industrial Development Authority/Agency
IDB  Industrial Development Bond
IDC  Industrial Development Corp
IDRB  Industrial Development Revenue Bond
IO  Interest Only security for which the fund receives interest on notional principal (par)
PCR  Pollution Control Revenue
FFA  Public Finance Authority
PIK  Payment-in-kind
PTC  Pass-Through Certificate
RAC  Revenue Anticipation Certificate
RAN  Revenue Anticipation Note
RAW  Revenue Anticipation Warrant
REIT  Real Estate Investment Trust
RIB  Residual interest bond issued by a third party securitization trust and purchased directly through a cash transaction that involved no exchange of previously held securities; rate varies inversely to short-term rates and the rate presented is the effective rate at period-end
STEP  Stepped coupon bond for which the coupon rate of interest will adjust on specified future dates(s)
TAN  Tax Anticipation Note
TAW  Tax Anticipation Warrant
TBA  To Be Announced purchase commitment
TDFA  Trade & Deposit Facility Agreement
TECP  Tax-Exempt Commercial Paper
TRAN  Tax Revenue Anticipation Note
VR  Variable Rate; rate shown is effective rate at period end
VRDN  Variable Rate Demand Note under which the holder has the right to sell the security to the issuer or the issuer’s agent at a predetermined price (generally par) on specified dates upon required notification; rate shown is effective rate at period-end

Important Information
The portfolio data contained herein is for informational purposes only and does not constitute a recommendation or an offer for a particular security or investment. Unlike the fund's regulatory filings, the portfolio data and its presentation in this document do not conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. The holdings are not audited and the information may differ in certain respects, such as derivatives exposure and security name, from the information found in the complete list of portfolio investments in the semiannual and annual shareholder reports and Form N-Q.